HSPPC-96: Clinical Trials

2 trials of HSPPC-96, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 withdrawn. 2 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 12Completed 1, Withdrawn 1
Phase 22Completed 1, Withdrawn 1

Follow HSPPC-96: new trials by email Literature Review of HSPPC-96 trials Research Report on HSPPC-96

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma
ipilimumab, HSPPC-96 - Melanoma
Phase 1 / Phase 2WithdrawnRabih Said2015-12-012016-01-25
GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma
HSPPC-96, Standard Surgical Resection - Brain and Central Nervous System Tumors
Phase 1 / Phase 2CompletedUniversity of California, San Francisco962005-11-182021-05-13

Conditions studied

Brain Neoplasms (1)  ·  Central Nervous System Neoplasms (1)  ·  Glioblastoma (1)  ·  Melanoma (1)

Sponsors

Rabih Said (1)  ·  University of California, San Francisco (1)

Countries

United States (2)

Top investigators

Jennifer Clarke, MD (1)  ·  Rabih Said, MD, MPH (1)

Results publications

PMID 24335700

NIH funding

P50CA097257 (1), R01CA164714 (1)